Cytologic and Immunohistochemical Evaluation of Low-Grade Spindle Cell Lesions of the Gastrointestinal Tract.

Spindle cell lesions of the gastrointestinal tract are relatively uncommon compared with the frequency of their epithelial counterparts. Although gastrointestinal stromal tumors and leiomyomas are the most commonly encountered spindle cell lesions in the stomach and esophagus, respectively, there are other less common diagnostic entities that should be considered for accurate diagnoses as well as appropriate patient treatment and clinical follow-up. Given the morphologic overlap of low-grade spindle cell lesions on cytologic preparations, ancillary studies play a key role in differentiating these lesions from one another.

Prospective evaluation of impact of using the Bethesda System for Reporting Thyroid Cytopathology: an institutional experience.

INTRODUCTION: The Bethesda System for Reporting Thyroid Cytology (BSRTC) refines the definition of and provides specific diagnostic criteria for fine-needle aspiration (FNA) assessment of thyroid lesions. This study was conducted to prospectively evaluate the diagnostic and clinical impact of using BSRTC for management of thyroid lesions and to compare diagnostic performance of post-BSRTC period with that of pre-BSRTC period. MATERIALS AND METHODS: The study included FNA specimens obtained in our institution 2.5 years prior to and 2.5 years after implementing BSRTC. Nondiagnostic rate, distribution of the diagnostic categories, rate of surgical follow-up, cytohistologic concordant rate, and risk of malignancy were calculated and compared between pre- and post-BSRTC periods. RESULTS: In comparison to the pre-BSRTC period, the post-BSRTC period generated a lower nondiagnostic rate (19.9% versus 15.8%), a greater proportion of benign (65.3% versus 69.2%) and atypia of undetermined significance or follicular lesion of undetermined significance (4.4% versus 7.4%) in contrast with a decreased proportion of follicular neoplasm or suspicious for follicular neoplasm categories (5.6% versus 2.2%). Rate of surgical follow-up decreased for benign (13.8% versus 7.6%) and atypia of undetermined significance or follicular lesion of undetermined significance (61.5% versus 42.1%) categories, and overall surgical rate reduced (24.2% versus 18.1%). Implementation of BSRTC did not affect overall rate of cytohistologic concordance (78.4% versus 80.5%) or the overall rate of histologically proven malignancy (30.6 versus 36.9%), whereas the individual cytohistologic concordant rate and the malignant rate for each of the diagnostic categories did not differ between pre- and post-BSRTC. CONCLUSIONS: The implementation of BSRTC resulted in a decreased overall surgical rate, particularly for benign and follicular lesion of undetermined significance categories, without affecting overall cytohistologic concordance and rate of malignancy.

Characterization of type III TGF-ß receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer.

Invasive breast carcinomas are heterogeneous and exhibit distinct molecular features and biological behavior. Understanding the underlying molecular events that promote breast cancer progression is necessary to improve treatment and prognostication. TGF-ß receptor III (TBR3) is a member of the TGF-ß signaling pathway, with functions in cell proliferation and migration in malignancies, including breast cancer. Recent studies propose that TBR3 may function as a tumor suppressor and that its loss may correlate with disease progression. However, there are limited data on the expression of TBR3 in breast cancer in relationship to tumor type, hormonal receptor status and HER-2/neu, and patient outcome. In this study, we investigated the expression of TBR3 in a cohort of 205 primary invasive breast carcinomas in tissue microarrays (TMAs), with comprehensive clinical, pathological and follow- up information. Sections were stained for TBR3 and evaluated for intensity of reactivity based on a 4-tiered scoring system (1 to 4; TBR3 low = scores 1-2; TBR3 high = scores 3-4). Of the 205 invasive carcinomas, 123 were luminal type (95 type A, 28 type B), 8 were HER-2 type, and 62 were triple negative (TN). TBR3 was high in 112 (55 %) and low in 93 (45 %) cases. Low TBR3 was associated with higher histological grade and worse disease free and overall survival, all features of biologically aggressive breast carcinomas. TBR3 was significantly associated with the subtype of breast cancer, as low TBR3 was detected in 95 % of TN compared to 22 % of luminal tumors (p < 0.0001). We discovered a significant association between low TBR3 protein expression, TN breast cancer phenotype, and disease progression. These data suggest that TBR3 loss might be linked to the development of TN breast cancers and pave the way to investigating whether restoring TBR3 function may be a therapeutic strategy against TN breast carcinomas.

Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens.

CONTEXT: Prostate cancer (PC) with lymph node metastases (LN(+)) is relatively rare, whereas it is relatively common in disease with a Gleason score (GS) 8 to 10 and virtually never seen in PC with GS 6 or less. It is most variable in GS 7 PC. OBJECTIVE: To determine clinicopathologic features associated with GS 7 PC with LN(+) compared with a control group without lymph node metastases (LN(-)). DESIGN: We analyzed 184 GS 7 radical prostatectomies with LN(+) and the same number of LN(-) Gleason-matched controls. The LN(+) cases were GS 3 + 4 = 7 (n = 64; 34.8%), GS 4 + 3 = 7 (n = 66; 35.9%), GS 3 + 4 = 7 with tertiary 5 (n = 10; 5.4%), and GS 4 + 3 = 7 with tertiary 5 (n = 44; 23.9%). RESULTS: The LN(+) cases demonstrated higher average values in preoperative prostate-specific antigen (12.2 versus 8.1 ng/mL), percentage of positive biopsy cores (59.1% versus 42.9%), prostate weight (54.4 versus 49.4 g), number of LNs submitted (12.7 versus 9.4), incidence of nonfocal extraprostatic extension (82.6% versus 63.6%), tumor volume (28.9% versus 14.8%), frequency of lymphovascular invasion (78.3% versus 38.6%), intraductal spread of carcinoma (42.4% versus 20.7%), incidence of satellite tumor foci (16.4% versus 4.3%), incidence of pT3b disease (49.5% versus 14.7%), and lymphovascular invasion in the seminal vesicles (52% versus 30%). There were differences in GS 4 patterns and cytology between LN(+) and LN(-) cases, with the former having higher volumes of cribriform and poorly formed patterns, larger nuclei and nucleoli, and more-frequent macronucleoli. All P ≤ .05. CONCLUSION: Gleason score 7 PC with LN(+) has features highlighting a more-aggressive phenotype. These features can be assessed as prognostic markers in GS 7 disease on biopsy (eg, GS 4 pattern, intraductal spread, cytology) or at radical prostatectomies (all variables), even in men without LN dissection or LN(-) disease.